Davion Appoints New Chairman, Chief Operating Officer, and a Non-Executive Director

Monday 13 November, 2023

13th November 2023 - Nicosia, Cyprus

Press Release

For Immediate Release

Davion Healthcare Plc

("Davion" or the "Company")

Davion Appoints New Chairman, Chief Operating Officer, and a Non-Executive Director

Davion Healthcare Plc, a leading medical device manufacturer, is pleased to announce that it has appointed Sir Eric Peacock as Chairman of the company with immediate effect and has also appointed to the board Mr Jon Chadwick as Chief Operating Officer along with Mr Julian F. Sluyters as a Non-Executive Director.

Sir Eric Peacock is the Chairman of IPro Sport Holdings Ltd (hydration drinks), Buckley Jewellery Ltd, Stevenage Packaging Ltd, Kingfisher Beer Europe Ltd and is the Senior Non-Executive Director of Bango Plc.

He was formerly a Non-Executive Director at the government business United Kingdom Export Finance and has previously sat on a number of other government boards namely United Kingdom Trade and Investment, Foreign and Commonwealth Office and the Department for Innovation and Skills. He has a wide ranging experience of start up's, turnarounds, financing, acquiring, disposal and floatation with a significant international background having run businesses in Australia, New Zealand, South Africa, France and Ireland.

Sir Eric was knighted in 2003 for his services to International Trade.

He is also Chairman of the charity The Big Cat Sanctuary and the charities Uniqueness and The AB Trust both of which focus on disadvantaged children and young adults.

Mr Jon Chadwick brings nearly three decades of experience in the financial services industry, with a notable shift in focus towards the dynamic fields of Med Tech and Bio Tech since 2019. His journey began in the intricate realm of financial services, where he honed his skills and developed a keen understanding of the industry's complexities. Over the years, Jon's professional trajectory evolved organically, aligning with his growing passion for innovation and cutting-edge technologies in the realms of Medical Technology and Biotechnology.

In the ever-evolving landscape of Bio and Med Tech, Jon has established himself as a seasoned professional with a knack for identifying opportunities and driving impactful strategies. His transition from the traditional financial sector to the forefront of these ground breaking industries, reflects his adaptability and commitment to staying ahead of the curve. With a reputation for fostering collaborative partnerships and leveraging his extensive network, Jon continues to navigate the intricate intersections of finance and innovation, contributing to the growth and success of businesses at the intersection of Med Tech and Bio Tech.

Mr Julian F. Sluyters has had a 40-year career in the financial services industry, initially in public accounting, specializing in banks, asset management firms, and mutual funds. Over the past three decades, he held various leadership roles in asset management firms, including CEO positions in global mutual fund and European fund services companies. He has extensive board experience, having served on over 20 different mutual fund boards in the US and Europe and as a Trustee for five boards. Mr. Sluyters is also an audit committee financial expert and has expertise in private equity and alternative asset classes. He currently advises EQX Biome, a biodiversity impact company. Julian is based in the United States.

Jack Kaye, Davion's CEO said "I am delighted to welcome Sir Eric Peacock, Mr Jon Chadwick and Mr

Related Sectors:

Business & Finance ::

Related Keywords:

Davion :: Appointments ::

Scan Me:

Julian Sluyters to the Davion Board. I know they will all make valuable contributions to the ongoing success of the company."

In addition to these three board appointments, there will be further appointments in the course of the next month to ensure the company meets its regulatory requirements with respect to the structure of its Board of Directors and the general governance of the company, in preparation for the listing of its ADR's on the NASDAQ stock exchange early next year The company remains committed to delivering exceptional value to its shareholders whilst driving innovation within the medical sector.

THE DIRECTORS OF THE ISSUER ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT

Press inquiries please contact:

Davion Healthcare Plc

Munro Forbes – Media Relations Manager

E: munro.forbes@davionhealthcare.com

Editors Note:

Davion Healthcare – transforming the ordinary into the extraordinary

"Our mission is to create and manage an environment for the secure development of new medical devices.

With a current focus on accessible products available for self-use in the comfort of your own home utilising smart technology interfaces, we are committed to empowering individuals to take control of their health and well-being by providing them with the tools they need to detect potential health issues at an early stage.

We just happen to make great medical devices that can make a difference in people's lives."

Company Contact:

Davion Healthcare Plc

T. +357 25 040 052
E. admin@davionhealthcare.com
W. https://davionhealthcare.com

View Online

Newsroom: Visit our Newsroom for all the latest stories:
https://www.davion.pressat.co.uk